StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) company profile

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)

Close on Nov 17, 2026Market cap $1.49MP/E –Yield –

About Kairos Pharma

Pharmaceutical Preparations, SIC 2834

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that advances therapeutics designed to overcome immune suppression and drug resistance in cancer patients. Its development pipeline includes antibodies, small molecules, and cell therapies targeting indications such as prostate cancer, lung cancer, breast cancer, and glioblastoma. The company's lead candidates include ENV 105, an antibody targeting CD105 to counter resistance in prostate and non-small cell lung cancers, and ENV 205, which targets extracellular mitochondrial DNA to address chemotherapy resistance. Its pipeline also features immunotherapeutic candidates such as KROS 101, an oral small-molecule GITR ligand modulator, and KROS 201, a dendritic-cell-activated T cell therapy for glioblastoma.

The company conducts clinical trials across multiple medical centers, including Cedars-Sinai Medical Center, the University of Utah, and City of Hope. Aside from off-site clinical trials performed at third-party facilities, its operations are conducted virtually. Kairos Pharma maintains its principal executive offices in Los Angeles, California.

Summary of the business section of Kairos Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Kairos Pharma, LTD.
Headquarters
Los Angeles, CA
Address
2355 Westwood Blvd. #139 90064
Phone
(818) 404-5541
Employees
1, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLP, Los Angeles, CA

Stock & identifiers

Ticker
KAPA
Exchange
NYSE
IPO date
Sep 17, 2024
Shares outstanding
24M, Aug 12, 2026
Public float
$6.90M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-7 reverse, Sep 1, 2026
SEC CIK
1962011
FIGI
BBG01JLR1R85
Share class FIGI
BBG01JLR1S38
EIN
46-2993314

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John S. YuCEO and Chairman, Director5,546,677
Neil BhowmickChief Scientific Officer1,311,739
Doug SamuelsonChief Financial Officer293,039
Ramachandran MuraliVP of Research and Development299,529
Hyun W. BaeDirector73,370
Rahul SinghviDirector49,204
Hansoo Michael KeyoungDirector29,084

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsTotalvs. prior year
John S. Yu$200.00K$87.50K$75.42K$362.92K+323%
Neil Bhowmick$106.25K$50.00K$69.17K$225.42K+210%
Ramachandran Murali$87.50K$40.00K$62.92K$190.42K+198%
Doug Samuelson$62.50K$50.00K$142.25K$254.75K+85%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 17, 2024
Offer price
$4.00
Securities offered
1,550,000
Gross proceeds
$6.20M
Exchange
NYSE American
First trading day
Sep 16, 2024
First-day close
$2.60-35.0%
Lock-up ends (est.)
Mar 15, 2025

“We are offering 1,550,000 shares of our common stock at an initial public offering price of $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had one full-time employee, our Chief Financial Officer, and three part-time employees (including our executive officers), each of whom is a part-time employee primarily engaged in research and development activities, and all hold M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?